Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Chunyan Zhang 1 Article
Soluble Axl Is a Novel Diagnostic Biomarker of Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection
Xiaoting Song, Ailu Wu, Zhixiao Ding, Shixiong Liang, Chunyan Zhang
Cancer Res Treat. 2020;52(3):789-797.   Published online March 5, 2020
DOI: https://doi.org/10.4143/crt.2019.749
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate the diagnostic value of soluble Axl (sAxl) in hepatocellular carcinoma (HCC) in comparison with serum α-fetoprotein (AFP).
Materials and Methods
Eighty HCC patients, 80 liver cirrhosis patients (LC), 80 patients with hepatitis B virus (HBV) infection, and 80 healthy controls (HC) were enrolled. sAxl levels were measured by an enzyme-linked immunosorbent assay, serum AFP levelswere measured by an electrochemiluminescence immunoassay. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic performances.
Results
The results show that levels of sAxl were high expression in patients with HCC (p < 0.05), varied with disease state as follows: HCC > LC > HC > HBV. Logistic regression and ROC curve analysis identified the optimal cut-off for sAxl in differentiating all HCC and non-HCC patients was 1,202 pg/mL (area under the receiver operating characteristic [AUC], 0.888; 95% confidence interval [CI], 0.852 to 0.924) with sensitivity 95.0%, specificity 73.3%. Furthermore, differential diagnosis of early HCC with non-HCC patients for sAxl showed the optimal cut-off was 1,202 pg/mL (AUC, 0.881; 95% CI, 0.831 to 0.931; sensitivity, 94.1%; specificity, 73.3%). Among AFP-negative HCC patients with non-HCC patients, the cut-off was 1,301 pg/mL (AUC, 0.898; 95% CI, 0.854 to 0.942) with a sensitivity of 84.6%, a specificity of 76.3%. The optimal cut-off for sAxl in differentiating all HCC and chronic liver disease patients was 1,243 pg/mL (AUC, 0.840; 95% CI, 0.791 to 0.888) with sensitivity 93.8%, specificity 61.9%. The combination of AFP and sAxl increased diagnostic value for HCC.
Conclusion
sAxl outperforms AFP in detecting HCC, especially in early HCC and in AFP-negative HCC. Combination sAxl with AFP improved the specificity for early HCC diagnosis. In summary, sAxl is a candidate serum marker for diagnosing HCC.

Citations

Citations to this article as recorded by  
  • Biomarker in Hepatocellular Carcinoma
    Pooja Basthi Mohan, Rajiv Lochan, Shiran Shetty
    Indian Journal of Surgical Oncology.2024; 15(S2): 261.     CrossRef
  • From MASH to HCC: the role of Gas6/TAM receptors
    Daria Apostolo, Luciana L. Ferreira, Federica Vincenzi, Nicole Vercellino, Rosalba Minisini, Federico Latini, Barbara Ferrari, Michela E. Burlone, Mario Pirisi, Mattia Bellan
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • GAS6/TAM Axis as Therapeutic Target in Liver Diseases
    Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí
    Seminars in Liver Disease.2024; 44(01): 099.     CrossRef
  • Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH
    Sturla Magnus Grøndal, Anna Tutusaus, Loreto Boix, Maria Reig, Magnus Blø, Linn Hodneland, Gro Gausdal, Akil Jackson, Pablo Garcia de Frutos, James Bradley Lorens, Albert Morales, Montserrat Marí
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Evaluating soluble Axl as a biomarker for glioblastoma: A pilot study
    Daniel Raymond, Melanie Fukui, Samuel Zwernik, Amin Kassam, Richard Rovin, Parvez Akhtar, Salvatore V. Pizzo
    PLOS ONE.2024; 19(7): e0301739.     CrossRef
  • A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma
    Bing-yao Pang, Yan Leng, Xiaoli Wang, Yi-qiang Wang, Li-hong Jiang
    Annals of Medicine.2023; 55(1): 42.     CrossRef
  • Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review
    Endrit Shahini, Giuseppe Pasculli, Antonio Giovanni Solimando, Claudio Tiribelli, Raffaele Cozzolongo, Gianluigi Giannelli
    International Journal of Molecular Sciences.2023; 24(5): 4286.     CrossRef
  • AXL in cancer: a modulator of drug resistance and therapeutic target
    Yaoxiang Tang, Hongjing Zang, Qiuyuan Wen, Songqing Fan
    Journal of Experimental & Clinical Cancer Research.2023;[Epub]     CrossRef
  • Emerging biomolecules for practical theranostics of liver hepatocellular carcinoma
    Miner Hu, Xiaojun Xia, Lichao Chen, Yunpeng Jin, Zhenhua Hu, Shudong Xia, Xudong Yao
    Annals of Hepatology.2023; 28(6): 101137.     CrossRef
  • Gas6 in chronic liver disease—a novel blood-based biomarker for liver fibrosis
    Katharina Staufer, Heidemarie Huber, Jasmin Zessner-Spitzenberg, Rudolf Stauber, Armin Finkenstedt, Heike Bantel, Thomas S. Weiss, Markus Huber, Patrick Starlinger, Thomas Gruenberger, Thomas Reiberger, Susanne Sebens, Gail McIntyre, Ray Tabibiazar, Amato
    Cell Death Discovery.2023;[Epub]     CrossRef
  • TAM Receptors in the Pathophysiology of Liver Disease
    Emilio Flint, Evangelos Triantafyllou, Christine Bernsmeier
    Livers.2022; 2(1): 15.     CrossRef
  • Prognostic Value of Computed Tomography Texture Features in Patients with Hepatocellular Carcinoma Following Stereotactic Ablative Radiotherapy
    Yufeng Zhu, Jie He, Xingcai Luo
    Iranian Journal of Radiology.2022;[Epub]     CrossRef
  • Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease
    Agostino Colli, Tin Nadarevic, Damir Miletic, Vanja Giljaca, Mirella Fraquelli, Davor Štimac, Giovanni Casazza
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Accelerating AXL targeting for TNBC therapy
    Lohit Khera, Sima Lev
    The International Journal of Biochemistry & Cell Biology.2021; 139: 106057.     CrossRef
  • Hepatocellular Carcinoma in 2021: An Exhaustive Update
    Cyriac A Philips, Sasidharan Rajesh, Dinu C Nair, Rizwan Ahamed, Jinsha K Abduljaleel, Philip Augustine
    Cureus.2021;[Epub]     CrossRef
  • AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization
    Tugce Batur, Ayse Argundogan, Umur Keles, Zeynep Mutlu, Hani Alotaibi, Serif Senturk, Mehmet Ozturk
    International Journal of Molecular Sciences.2021; 22(24): 13247.     CrossRef
  • New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma
    Ting Wang, Kun-He Zhang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • 7,841 View
  • 188 Download
  • 18 Web of Science
  • 17 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP